ILS selects Provantis for fully automating toxicology data acquisition, analysis and reporting processes

Instem, a leading provider of early drug development software solutions, announced today that Integrated Laboratory Systems (ILS) has subscribed to Provantis™ Online, enhancing their existing software systems.

“Instem’s hosted solution is a true turn-key system, so the time required by our staff to get their system validated and into production is significantly reduced”

Headquartered in Research Triangle Park, North Carolina, ILS is a multidisciplinary research organization providing comprehensive support to federal and commercial clients in the environmental and health sciences.

After reviewing all commercial alternatives within the preclinical IT market, ILS chose Provantis™ as the most comprehensive solution to fully automate their toxicology data acquisition, analysis and reporting processes. By using Provantis™, they will be able to reduce costs, execute more studies and deliver increased value in shorter timeframes to their sponsors.

“Instem’s hosted solution is a true turn-key system, so the time required by our staff to get their system validated and into production is significantly reduced,” comments Brad Blackard, COO at ILS. “We felt that using Provantis™ over the Web provided the best fit for our business model and allowed our limited IT resources to be leveraged more efficiently.”

Using Instem’s hosted remote delivery model offers simpler, more cost effective ways to provide software functionality, maintenance, and support over the Internet. ILS will have complete in-application access to their data just as if their software was deployed on-site, yet they no longer require additional hardware or dedicated resources. Removing the need for on-site software ensures clients like ILS can access the latest major releases of Provantis™ without the delays and costs traditionally involved with site-based installations.

Instem’s turn-key subscription includes all 3rd party licenses such as Oracle, Outlook and SAS, along with training, maintenance, unlimited help desk support and Instem’s Validation Pack.

Since 2005, Instem has utilized a military-grade data center based in the US, which is being used by clients running GLP and non-GLP studies.

ILS will additionally be taking advantage of Instem’s Specialized Solution services, a more tailored approach to deployment, offering dedicated client specialists and extended customer care. This program features the Continuous Learning Model, where clients stay closely connected for one year following their first study using Provantis™, with on-demand access to industry specialists to assist with new study designs, refresher learning or anything else needed to optimize their use of Instem solutions.

Provantis™ is a modern, fully integrated software system for single users and global organizations engaged in preclinical evaluation studies. Orchestrating every facet of preclinical drug safety assessment, Provantis™ streamlines processes and workflows with straightforward, intuitive functionality for simple or complex studies within a GLP or non-GLP environment, on-site or over the Web.

Instem & ILS welcomes anyone wanting more information to visit them at this year’s 49th annual ToxExpo in Salt Lake City, Utah at booths 1201 & 2118.

Source Integrated Laboratory Systems

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research suggests no need for yellow fever vaccine booster after initial dose